Merck partners with American Cancer Society to address cancer in women

MerckMerck, a leading science and technology company, and the American Cancer Society (ACS) today released a report that shows all four of the top causes of cancer deaths in women worldwide are mostly preventable or can often be detected early, when treatment is more successful. The report, titled "The Global Burden of Cancer in Women," is the first tangible output from an innovative partnership between Merck and the American Cancer Society focused on raising awareness and strengthening advocacy around women’s cancers.

"We are proud to partner with the American Cancer Society to address the impact cancer has on women worldwide," said Belén Garijo, member of the Executive Board and CEO Healthcare at Merck. "This collaboration is a first-of-its-kind public-private partnership that recognizes that no one sector can tackle this challenge alone. Improving women’s health and well-being has an uplifting ripple effect on our world, and we know when women do better, our communities do better."

The research examines the increasing impact of cancer among women in low- and middle-income countries - and outlines potential solutions to minimize the economic and societal impact of the disease for women, their families and healthcare systems.

Cancer is the second leading cause of death in women, with breast, colorectal, lung and cervical cancers claiming the most lives each year. With cancer rates on the rise as the global population grows and ages, the number of women who will lose their lives to cancer is expected to increase, particularly in low- and middle-income countries. In 2012, there were 3.5 million deaths among women due to cancer; by 2030 that number is expected to increase to 5.5 million deaths - a more than 57% increase in less than two decades. Increased education and prevention efforts will be essential to addressing this growing global health crisis.

"It's incumbent upon both the public and private sectors, as members of the global health community, to find ways to reduce the impacts of cancer on women by increasing prevention and treatment, saving the lives of women across the globe," said Ambassador Sally Cowal, senior vice president, global cancer control at the American Cancer Society.

In addition to the physical challenges women with cancer and their families experience, the burden of cancer also extends to the economy. The study found that in 2009, the global economic burden of cancer was estimated at about $ 286 billion, and much of that cost was due to premature death of members of the workforce. In the United States alone in 2008, years of productive life lost due to cancer in women corresponded to $ 82 billion, not to mention the many professional achievements that might have been realized.

The report was released at the World Cancer Congress during a Merck panel moderated by Ambassador Cowal. Other participants included HRH Princess Dina Mired of Jordan; Dr. Alise Reicin, Head of Global Clinical Development in the biopharma business of Merck; and Dr. Edward L. "Ted" Trimble, director, Center for Global Health at the National Cancer Institute.

This partnership will also catalyse the evolution of the American Cancer Society's All of Me Young Scholars program, which aims to educate and cultivate health and civil society professionals in Brazil, Mexico, Colombia and India to affect meaningful change in prevention and early detection of cancers among women in low- and middle-income countries.

This report is part of Merck's involvement with the Healthy Women, Healthy Economies initiative, which explicitly links the issue of women’s health and well-being with economic growth. The full "Global Burden of Cancer in Women" report is available here.

About the Healthy Women, Healthy Economies Initiative
Merck is a founding partner of the Healthy Women, Healthy Economies initiative, which brings together the evidence about women's health and well-being and its impact on economic growth with the best practices that governments, employers and non-governmental organizations can follow. It aims to identify and implement policies that advance women's health and well-being to increase their economic participation in the societies in which they live.

About the American Cancer Society
The American Cancer Society is a global grassroots force of more than three million volunteers saving lives and fighting for every birthday threatened by every cancer in every community. As the largest voluntary health organization, the Society's efforts have contributed to a 20 percent decline in cancer death rates in the U.S. since 1991, and a 50 percent drop in smoking rates. Thanks in part to our progress, nearly 14 million Americans who have had cancer and countless more who have avoided it will celebrate more birthdays this year. We're determined to finish the fight against cancer. We're finding cures as the nation’s largest private, not-for-profit investor in cancer research, ensuring people facing cancer have the help they need and continuing the fight for access to quality health care, lifesaving screenings, clean air and more.

About the American Cancer Society’s All of Me Young Scholars Program
The American Cancer Society’s All of Me Young Scholars program aims to educate and cultivate young health and civil society professionals around the world to bring their energy, voice and new ideas to the new and growing field of integration of women's cancer prevention and early detection.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...